Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study.

Aim: Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, has demonstrated efficacy in randomized trials for plaque psoriasis, but real-world data in Asian populations remain limited. This 24-week prospective real-world cohort study evaluated the effectiveness and safety of deucravacitinib in 101 Chinese adults with plaque psoriasis treated with 6 mg once daily. Materials and methods: The prespecified primary endpoint was PASI75 at week 24. Secondary outcomes included PASI90, PASI100, PASI ≤1, and sPGA 0/1 at week 24. Results: At baseline, 68.3% of patients had PASI <10. At week 24, 77.2% achieved PASI75, 58.4% achieved PASI90, and 22.8% achieved PASI100; 81.2% achieved PASI ≤1 and 83.2% achieved sPGA 0/1. A post hoc exploratory analysis suggested numerically higher response rates in patients with predominant small plaque morphology. Treatment was generally well tolerated, with no serious adverse events or discontinuations. Mild pruritic eruptions were infrequent and occurred mainly in individuals with atopic backgrounds. Conclusions: These findings support the real-world effectiveness and safety of deucravacitinib in Chinese patients with plaque psoriasis; morphological observations are exploratory and hypothesis-generating.